Every year, millions of dollars are invested by pharmaceutical research and development companies due to clinical trial failures. All the capital invested on research development and experimental procedures is totally lost, when these clinical research trials fail for various reasons.
Most medical research trials for new drugs look promising enough during the phase 1 and phase 2 pivotal clinical trials. However, once they move towards the final phase-3 stage, the trials seem to dwindle out. Trial failures may be attributed to inappropriate patient population, poor infrastructure, lack of core fundamental understanding of the research, lack of staff motivational factors, and lack of technical support to name a few points.
Clinical trial process can be made more efficient and easier by adopting the following measures:
Do not forget to adjust the sampling size of the new drug during clinical trials to be on the safer side. Likewise, predicting possible drug interactions between other drug compounds can be minimized by taking into account the physical theoretical view.
Clinical testing is imperative for the development of new drug process, so as to gain official approval by FDA. Modern clinical trials are planned in a careful manner, and researchers are collecting sufficient and relevant data through non-clinical research and development.